Amgen Secures European Approval for UPLIZNA in Generalized Myasthenia Gravis
Event summary
- European Commission approves Amgen's UPLIZNA for generalized myasthenia gravis (gMG) on February 12, 2026.
- UPLIZNA is the first and only CD19-targeted therapy approved in Europe for anti-AChR+ and anti-MuSK+ gMG patients.
- Approval based on Phase 3 MINT trial data showing significant improvements in MG-ADL and QMG scores.
- Twice-yearly maintenance dosing offers a convenient treatment option for long-term disease control.
- UPLIZNA previously approved for IgG4-RD and NMOSD, expanding Amgen's rare disease portfolio.
The big picture
Amgen's UPLIZNA approval in Europe marks a strategic milestone in the treatment of generalized myasthenia gravis, a rare autoimmune disease with limited therapeutic options. The approval builds on UPLIZNA's established efficacy in other rare autoimmune conditions, positioning Amgen as a key player in the biotech space focused on targeted therapies. The convenience of twice-yearly dosing and the potential to reduce long-term steroid use address significant unmet needs in gMG management.
What we're watching
- Market Expansion
- Whether Amgen can leverage UPLIZNA's approval to gain market share in Europe's gMG treatment landscape.
- Clinical Efficacy
- The long-term efficacy and safety of UPLIZNA in reducing steroid dependence and managing gMG symptoms.
- Portfolio Diversification
- How this approval fits into Amgen's broader strategy of expanding its rare disease and autoimmune portfolio.